Bacteria‐Mediated Targeted Delivery and Deep Tumor Penetration of a Pt(IV)‐Drug Enables Synergistic Chemo‐Immunotherapy
Angewandte Chemie International Edition · 2026
DOI: 10.1002/anie.1710587 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2026. Verfasst von He Meng und 13 weiteren Autor:innen. Beteiligte Einrichtung: MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, IGCME, School of Chemistry, Sun Yat-Sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Escherichia coli, Antineoplastic Agents, Immunotherapy, Cisplatin. Die Arbeit nennt 45 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
Platinum‐based drugs are clinically vital for cancer treatment but suffer from off‐target cytotoxicity and poor tumor penetration. To overcome these limitations, we designed a tumor‐targeted Pt(IV) drug‐bacteria conjugate ( Pt‐EcN‐HER2 ). This conjugate exploits the inherent tumor tropism of probiotic bacterium Escherichia coli Nissle 1917 (EcN) to achieve targeted accumulation and deep penetration within the tumor microenvironment (TME). Once localized, elevated intratumoral hydrogen peroxide (H 2 O 2 ) and glutathione (GSH) activate the Pt(IV) drug. Activation simultaneously releases cytotoxic cisplatin and an adenosine A2A receptor (A2AR) antagonist within the TME. The released cisplatin induces DNA damage and cell death, amplified by co‐occurring depletion of reductants, promoting multiple death pathways. Concurrently, the A2AR antagonist competitively blocks adenosine‐mediated immunosuppressive signaling, activating immune cells in TME. This dual chemo‐immunotherapeutic action enables effective tumor eradication. The bacteria‐mediated delivery strategy fundamentally addresses penetration barriers, enhances tumor‐specific Pt(IV) drug delivery and activation, mitigates systemic toxicity, and overcomes TME immunosuppression, thereby significantly potentiating platinum‐based chemo‐immunotherapy for solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, IGCME, School of Chemistry, Sun Yat-Sen University, Guangzhou, China.
ORCID-Profile: He Meng, Bing Shi, Tao Ouyang, Yuxiang Lu, Xiyu Huang, Zong-Wan Mao, Wei Xia
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- National Key Research and Development Program of China
Zitieren
APA
Meng, H., Wang, J., Shi, B., Ouyang, T., Lu, K., Lin, W., Lu, Y., Wang, J., Huang, X., Zhao, H., Xiong, Y., Xu, Z., Mao, Z. W., & Xia, W. (2026). Bacteria‐Mediated Targeted Delivery and Deep Tumor Penetration of a Pt(IV)‐Drug Enables Synergistic Chemo‐Immunotherapy. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.1710587
Vancouver
Meng H, Wang J, Shi B, Ouyang T, Lu K, Lin W, et al. Bacteria‐Mediated Targeted Delivery and Deep Tumor Penetration of a Pt(IV)‐Drug Enables Synergistic Chemo‐Immunotherapy. Angewandte Chemie International Edition. 2026. doi:10.1002/anie.1710587
BibTeX
@article{Meng2026,
author = {Meng, He and Wang, Jinhui and Shi, Bing and Ouyang, Tao and Lu, Kai and Lin, Wenkai and Lu, Yuxiang and Wang, Jing and Huang, Xiyu and Zhao, Hailong and Xiong, Yufang and Xu, Zilong and Mao, Zong-Wan and Xia, Wei},
title = {Bacteria‐Mediated Targeted Delivery and Deep Tumor Penetration of a Pt(IV)‐Drug Enables Synergistic Chemo‐Immunotherapy},
journal = {Angewandte Chemie International Edition},
year = {2026},
doi = {10.1002/anie.1710587}
}
EUVIMED